Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond

Moreno, Víctor; Hernández, Tatiana; Miguel, Marı́a de; Doger, Bernard; Calvo, Emiliano

doi:10.1016/j.coph.2021.05.004

Cited by 20 publications

(17 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different from CD19, which is often used as a target for CAR-T therapy in hematologic tumors, the main targets of CART development in solid tumors include Mesothelin, GD2, HER2, GPC3, Claudin18.2(CLDN18.2) and so on. Most CAR-T studies in solid tumors have low response rates in the 0-25% range ( 88 ). Recently, the EMA granted prime eligibility to CAR T - cell product candidate CT041, which against the claudin18.2 protein (CLDN18.2) for the treatment of gastric/gastroesophageal junction cancer.…”

Section: Discussionmentioning

confidence: 99%

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

Min

2022

Front. Immunol.

View full text Add to dashboard Cite

Chimeric antigen receptor T cell (CAR-T) therapy for the treatment of hematologic tumors has achieved remarkable success, with five CAR-T therapies approved by the United States Food and Drug Administration. However, the efficacy of CAR-T therapy against solid tumors is not satisfactory. There are three existing hurdles in CAR-T cells for solid tumors. First, the lack of a universal CAR to recognize antigens at the site of solid tumors and the compact tumor structure make it difficult for CAR-T cells to locate in solid tumors. Second, soluble inhibitors and suppressive immune cells in the tumor microenvironment can inhibit or even inactivate T cells. Third, low survival and proliferation rates of CAR-T cells in vivo significantly influence the therapeutic effect. As an emerging method, nanotechnology has a great potential to enhance cell proliferation, activate T cells, and restarting the immune response. In this review, we discuss how nanotechnology can modify CAR-T cells through variable methods to improve the therapeutic effect of solid tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

Min

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…However, cancer cells can generate suppressive factors including lymphocyte-activation gene 3 (LAG-3), TGF-b, prostaglandin E2 and IL-10 that inhibit immune response, thus escaping detection and clearance by the immune system (35). For patients whose immune systems fail to detect and response to cancer cells, adoptive cell therapy has been proved as effective strategies to treat advanced gastric cancer (36). Adoptive cell therapy utilizes various immune cells including tumour infiltrating lymphocytes (TILs), lymphokine-activated killer cells and cytokine-induced killer (CIK) cells to induce effective immunity to clear cancer cells (2,37).…”

Section: Adoptive Cell Therapymentioning

confidence: 99%

Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer

et al. 2022

View full text Add to dashboard Cite

As one of the most common forms of solid tumours, gastric carcinoma has been revealed as the third leading cause of death worldwide. The symptom of gastric cancer is usually not obvious and thus difficult to detect at earlier stages. Therefore, gastric cancer is already in the advanced stage once detected in patients, which has a poor prognosis due to ineffective therapies and multiple resistance. Recent advance in understanding the microenvironment of cancer has significantly promoted the development of immunotherapy for advanced gastric cancer. Immunotherapy can induce immune responses in gastric cancer patients thus leads to the destruction of cancer cells. In comparison of traditional therapy, immunotherapy has demonstrated robust efficacy and tolerable toxicity. Therefore, this novel strategy for treatment of advanced gastric cancer has gain increasingly popularity. In this review, we summarize recent progress of immunotherapy in advanced gastric cancer, such as immune check point inhibitors, adoptive cell therapy, VEGF inhibitors, cancer vaccines and CAR-T cell therapy. We highlight immunotherapies involved in clinical applications and discuss the existing challenges of current immunotherapies and promising strategies to overcome these limitations.

show abstract

“…It was only at the beginning of the 21st century that it became obvious that the presence of intratumoral T-lymphocytes was associated with a favorable prognosis of tumors [ 102 ]. Inspired by the unprecedented advances in cancer immunotherapy over the past decade, such as the success of immune checkpoint inhibitors (ICIs) and adoptive cell therapy with chimeric antigen receptor T cells, which revolutionized the treatment of hematological malignancies, many studies have started to use this “active immunotherapy” in solid tumors, but unfortunately, this method of treatment has not yet proved its sufficiency to achieve significant antitumor activity in these tumors [ 103 ].…”

Section: Her2 As a Target For Therapymentioning

confidence: 99%

“…These “first generation” CAR constructs demonstrated limited activity in vivo due to the poor persistence of T cells, which led to the addition of single (second generation) or multiple (third generation) costimulatory domains (CD28, 4-1BB and OX40…), which help increase the efficiency and delay the exhaustion of the cells, hence improving the antitumor activity of the cells. It is also worth noting that the particular molecular design of the CAR construct is a factor that greatly affects the potency of the developed cellular product [ 103 , 104 ].…”

Section: Her2 As a Target For Therapymentioning

confidence: 99%

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions

Alrhmoun

Сенников

2022

Cancers

View full text Add to dashboard Cite

The treatment of HER2-positive cancers has changed significantly over the past ten years thanks to a significant number of promising new approaches that have been added to our arsenal in the fight against cancer, including monoclonal antibodies, inhibitors of tyrosine kinase, antibody–drug conjugates, vaccination, and particularly, adoptive-T-cell therapy after its great success in hematological malignancies. Equally important is the new methodology for determining patients eligible for targeted HER2 therapy, which has doubled the number of patients who can benefit from these treatments. However, despite the initial enthusiasm, there are still several problems in this field represented by drug resistance and tumor recurrence that require the further development of new more efficient drugs. In this review, we discuss various approaches for targeting the HER2 molecule in cancer treatment, highlighting their benefits and drawbacks, along with the different mechanisms responsible for resistance to HER2-targeted therapies and how to overcome them.

show abstract

Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond

Cited by 20 publications

References 84 publications

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions

Contact Info

Product

Resources

About